Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property group of the Litigation Department in Seyfarth Shaw LLP’s Washington D.C. office. Dr. Fanelli focuses his practice on pharmaceutical patent litigation under the Hatch-Waxman Act with particular emphasis on developing Paragraph IV litigation strategies and biosimilar market assessment, patent identification, and litigation strategy. Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act.
Dr. Fanelli’s practice spans the chemical, pharmaceutical, and biotechnology industries, and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, and opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions.
Dr. Fanelli’s experience with the pharmaceutical and chemical technologies includes work with new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices. Dr. Fanelli also regularly handles IP issues attendant to mergers and acquisitions and financing for life sciences companies.
Dr. Fanelli has firsthand experience in translating technologies into a successful commercial ventures. While at Fanelli Haag, Dr. Fanelli was a co-founder of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Dean Fanelli and Thomas Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.
In addition, Dr. Fanelli has developed various patent portfolios for commercially relevant products including those directed to: Dificid® (fidaxomicin), which is currently marketed for the treatment of infections related to C. difficile, and Nexterone (amiodarone HCl), marketed for the treatment and prophylaxis of ventricular fibrillation.
Prior to founding Fanelli Haag, Dr. Fanelli was in private practice in the Washington D.C. office of an international law firm, where his work focused primarily on patent prosecution and counseling of clients in the pharmaceutical, chemical, veterinary, consumer products, and nutritional industries. Dr. Fanelli gained additional experience in strategic patent management and licensing while seconded in-house with an international pharmaceutical drug-delivery company and while at a major consumer product company.
Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society. He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.
- J.D., The George Washington University Law School
- Ph.D., Organic Chemistry, Temple University
- B.S., Chemistry, Villanova University
Rate : $$$$